Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | March 18, 2025 | March 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date March 18, 2025 · Filed March 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2035-03-18 | Direct | 157,600 |
Reported balance
After 2025-03-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-18 · Grant · Acquired 157,600 · Balance 157,600 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2: This option vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Reporting Person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F2: This option vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Reporting Person's continuous service as of each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2025 Filed Mar 20, 2025 16:14 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 157,600 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001447028-25-000077 · wk-form4_1742501645.xml · derivative · entry 1 Hasija Anuj · CIK 0002058570 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,600 Underlying: Common Shares · 157,600 shares Expires 2035-03-18 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2 · derivative.exercise_date: This option vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.